A Phase II Study of the Combination of Metronomic Docetaxel and Bevacizumab as 2nd Line Treatment in Patients With Small Cell Lung Cancer (SCLC).
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2015
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 06 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 20 Jul 2011 Planned End Date changed from 1 Jan 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.